CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies

References

• Chubb SP, Williams RA. Biochemical Analysis of Pleural Fluid and Ascites. Clin Biochem Rev. 2018;39(2):39–50.30473591
   PubMedGoogle Scholar
• Montori G, Coccolini F, Fugazzola P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience. J Gastrointest Oncol. 2018;9(2):241–253. doi:10.21037/jgo.2017.12.0429755762
   PubMed Web of Science ®Google Scholar
• Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–298.25940594
   PubMed Web of Science ®Google Scholar
• Klaver YL. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World j Gastroenterology. 2012;18(39):5489–5494. doi:10.3748/wjg.v18.i39.5489
   PubMed Web of Science ®Google Scholar
• van Baal J, van Noorden CJF, Nieuwland R, et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. j Histochemistry Cytochemistry. 2018;66(2):67–83. doi:10.1369/0022155417742897
   PubMed Web of Science ®Google Scholar
• Najah H, Lo Dico R, Dohan A, Marry L, Eveno C, Pocard M. A feasibility study of the use of computed virtual chromoendoscopy for laparoscopic evaluation of peritoneal metastases. Surg Endosc. 2017;31(2):743–751. doi:10.1007/s00464-016-5028-127324331
   PubMed Web of Science ®Google Scholar
• Schmidt S, Meuli RA, Achtari C, Prior JO. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT. Clin Nucl Med. 2015;40(5):371–377. doi:10.1097/RLU.000000000000076825783507
   PubMed Web of Science ®Google Scholar
• Trilling B, Cotte E, Vaudoyer D, et al. Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis. Dis Colon Rectum. 2016;59(7):615–622. doi:10.1097/DCR.000000000000058927270513
   PubMed Web of Science ®Google Scholar
• Rodriguez-Enriquez S, Pacheco-Velazquez SC, Gallardo-Perez JC, et al. Multi-biomarker pattern for tumor identification and prognosis. J Cell Biochem. 2011;112(10):2703–2715. doi:10.1002/jcb.2322421678471
   PubMed Web of Science ®Google Scholar
• Kim BC, Bae JH, Park SM, Won DY, Lee IK. Is ascites CEA a risk factor for peritoneal carcinomatosis in colorectal cancer?: a long-term follow-up study. Int J Colorectal Dis. 2020;35(1):147–155. doi:10.1007/s00384-019-03448-231802190
   PubMed Web of Science ®Google Scholar
• Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002;48(8):1151–1159. doi:10.1093/clinchem/48.8.115112142367
   PubMed Web of Science ®Google Scholar
• Zhang W, Tong Q, Wang X, Wang Q, Li S. T lymphocyte subsets determination and DNA ploidy analysis in the differential diagnosis between benign and malignant ascites. Cancer Invest. 2009;27(1):67–69. doi:10.1080/0735790080216106219160105
   PubMed Web of Science ®Google Scholar
• Zaini ZM, McParland H, Møller H, Husband K, Odell EW. Predicting malignant progression in clinically high-risk lesions by DNA ploidy analysis and dysplasia grading. Sci Rep. 2018;8(1):15874. doi:10.1038/s41598-018-34165-530367100
   PubMedGoogle Scholar
• Gilly FN, Cotte E, Brigand C, et al. Quantitative prognostic indices in peritoneal carcinomatosis. European Journal of Surgical Oncology (EJSO). 2006;32(6):597–601. doi:10.1016/j.ejso.2006.03.00216617003
   PubMed Web of Science ®Google Scholar
• Coccolini F, et al. Peritoneal carcinomatosis. World j Gastroenterology. 2013;19(41):6979–6994. doi:10.3748/wjg.v19.i41.6979
   PubMed Web of Science ®Google Scholar
• Matte I, Lane D, Bachvarov D, Rancourt C, Piche A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer. 2014;14(1):288. doi:10.1186/1471-2407-14-28824761768
   PubMedGoogle Scholar
• Hu Y, Qi C, Liu X, et al. Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Lett. 2019;457:142–150. doi:10.1016/j.canlet.2019.04.03431075288
   PubMed Web of Science ®Google Scholar
• Zheng L-N, Wen F, Xu P, Zhang S. Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis. World j Clin Cases. 2019;7(20):3247–3258. doi:10.12998/wjcc.v7.i20.324731667175
   PubMed Web of Science ®Google Scholar
• Bisht B, Handa U, Mohan H, Lehl SS. Complementary value of DNA flow cytometry and image morphometry in detection of malignant cells in effusion fluids. Malays J Pathol. 2014;36(2):83–90.25194530
   PubMed Web of Science ®Google Scholar
• Ahadi M, Tehranian S, Memar B, et al. Diagnostic value of carcinoembryonic antigen in malignancy-related ascites: systematic review and meta-analysis. Acta Gastroenterol Belg. 2014;77(4):418–424.25682632
   PubMed Web of Science ®Google Scholar
• Kaleta EJ, Tolan NV, Ness KA, O’Kane D, Algeciras-Schimnich A. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Clin Biochem. 2013;46(9):814–818. doi:10.1016/j.clinbiochem.2013.02.01023454392
   PubMed Web of Science ®Google Scholar
• Liu F, Kong X, Dou Q, et al. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Ann Hepatol. 2014;13(3):357–363. doi:10.1016/S1665-2681(19)30865-824756011
   PubMed Web of Science ®Google Scholar
• Kundu R, Handa U, Mohan H. Role of DNA flow cytometry and immunocytochemical analysis in diagnosis of malignant effusions. Diagn Cytopathol. 2012;40(10):887–892. doi:10.1002/dc.2167321485027
   PubMed Web of Science ®Google Scholar
• Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15(2):154–161. doi:10.1007/s10120-011-0091-821892754
   PubMed Web of Science ®Google Scholar
• Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol. 2013;20(2):506–514. doi:10.1245/s10434-012-2627-522941175
   PubMed Web of Science ®Google Scholar
• Liu D, Kong D, Li J, et al. HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect. J Ovarian Res. 2018;11(1):47. doi:10.1186/s13048-018-0402-329903044
   PubMedGoogle Scholar